NewVale Capital closes first fund with $167M to invest in life-sciences space
NewVale Capital LLC recently closed its oversubscribed inaugural fund with $167 million to deploy in support of companies that provide infrastructure to the biotechnology industry.
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
Medical-device firm Boulder iQ has nearly doubled its Boulder footprint with the purchase of a…
-
Edgewise Therapeutics Inc., a Boulder-based muscle disease biopharmaceutical company, increased its research and development spending…
-
OnKure Inc., a Boulder precision oncology company, and California-based Reneo Pharmaceuticals Inc. have completed a…
-
Arca Biopharma has completed its merger with Oruka Therapeutics Inc.
